Aprovasc, a hypertension combination drug co-developed by Handok and Sanofi Aventis Korea, will enter the market in earnest with reimbursement on the 1st of next month.

The product is a combination drug of ARB-class irbesartan, which was developed by Sanofi, and CCB-class amlodipine besylate. This is the first irbesartan-amlodipine combination released to the market.

It was approved in Korea in November last year and completed the reimbursement listing process time.

According to industry sources on the 23rd, three dosage forms of Aprovasc Tab will be listed starting on Feb. 1. The drug is indicated for essential hypertension in adult patients in whom blood pressure is not